FMR1 and fragile X syndrome: These data suggest that abnormal mGluR-mediated signaling in Fmr1 KO mice can be reversed by serotonin acting through 5-HT7 receptors, suggesting that selective 5-HT7 receptor agonists might become novel pharmacological tools for FXS therapy.